2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Leonie Voorwerk, discusses outcomes with the combination of atezolizumab plus carboplatin in metastatic lobular breast cancer, which was evaluated as part of the phase 2 GELATO trial.
Leonie Voorwerk, a PhD student at the Netherlands Cancer Institute, discusses outcomes with the combination of atezolizumab (Tecentriq) plus carboplatin in metastatic lobular breast cancer, which was evaluated as part of the phase 2 GELATO trial (NCT03147040).
In total, 22 patients received at least 1 cycle of atezolizumab and were available for further analysis, 5 of whom had triple-negative breast cancer (TNBC), according to Voorwerk. Among the 21 patients who were eligible for response evaluation, 4 patients experienced a partial response (PR), while 2 patients achieved stable disease for at least 6 months. This translated to an objective response rate of 19%, and a clinical benefit rate of 29%.
Additionally, investigators identified a median duration of response of 12 weeks, with 1 patient experiencing an ongoing response, Voorwerk says. At least 3 patients remained progression free at 6 months, meeting the primary end point of the trial. Among the 6 patients who experienced clinical benefit, defined as either PR or stable disease, 4 had TNBC.
Baseline stromal tumor-infiltrating lymphocytes and stromal CD8 counts were also investigated, Voorwerk adds. Although these factors were not associated with clinical benefit, a trend toward a higher PD-L1 expression was observed in patients who experienced clinical benefit with the regimen, Voorwerk concludes.